A promising drug for Alzheimer's patients is in phase 3 clinical trials, which is produced from algae and improves against 125% the intellect and against 85% functionality and is expected to be approved in three years.
This is the ALZ-801 (tramiprosate), which will be administered orally in pill form and as shown by the results of studies - among others- reduces hippocampal atrophy and inflammation. It seems, that it may be indicated for use mainly in patients with Alzheimer's disease who carry the apolipoprotein E e4 predisposing gene (ΑΡΟΕ e4) and possibly eye diseases, such as glaucoma and macular degeneration.
This was reported by the neurologist- psychiatrist, Aristotle University of Thessaloniki professor and president of the Panhellenic Alzheimer's Disease Federation Magda Tsolaki, on the occasion of its announcement, on "Ab remains a therapeutic target for Alzheimer's disease; The role of tramprosate ", at the 12th Panhellenic Congress of Alzheimer's Disease & 4the PICAD Mediterranean Conference on Neurodegenerative Diseases & MeCoND, whose work begins tomorrow.
"There are currently four drugs in clinical trials, το Aducanumab, το Gantenerumab, the BAN2401 and the ALZ-801. The first three are monoclonal antibodies and are injectable (intravenously or subcutaneously) while the fourth - namely the ALZ801 (tramiprosate)- is administered orally in pill form. The target of all four is insoluble oligomers, which are considered to be toxic. The effort is to use them, especially ALZ -801, in patients with APOE positive gene e4 (which is a genetic risk factor for Alzheimer's), to be able to see if these drugs have any effect on this homogeneous group of people. The first studies had good results and now the phase studies are running 3, which we expect to have, also, good results. But in order for them to be approved, the phase 3 study must be completed. ", notes Ms.. Tsolaki, referring to new drugs for Alzheimer's disease.
He also points out that the most promising of these drugs is ALZ-801 because it has finally been shown to improve 125% and functionality against 81%, while other drugs are in phase trials 3 improve intellect at most against 80-84% (ΒΑΝ2401) and functionality against 22-26%. He emphasizes that it is important, that while with the administration of monoclonal antibodies swelling has been observed in the brain, no similar problem was observed with ALZ-801.
"The ALZ-801 is the most promising. I believe that when it is released it will be used not only therapeutically but also for prophylaxis, because we can see if we have the APOE E4 gene on the chromosome 19 in DNA, and to know, if we have a genetic predisposition. If we have a genetic predisposition, we can take it. This preparation is produced from algae, is an herbal product approved in China and has mild side effects, such as dizziness, nausea and sometimes vomiting, if taken in large doses. With the administration of ALZ-801 it seems that the rate of hippocampal atrophy decreases and mentally there is an improvement 125%. It reduces inflammation and could really be used in indications like Down syndrome, in familial Alzheimer's disease with mutations, and possibly used in glaucoma and macular degeneration ", adds Ms.. Tsolaki.
Source of RES EIA